Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/121991
Title: | Structure-activity relationships of 2-arylquinazolin-4-ones as highly selective and potent inhibitors of the tankyrases | Authors: | Nathubhai, Amit Haikarainen, Teemu Hayward, Penelope C. Muñoz Descalzo, Silvia Thompson, Andrew S. Lloyd, Matthew D. Lehtiö, Lari Threadgill, Michael D. |
UNESCO Clasification: | 32 Ciencias médicas 3209 Farmacología |
Keywords: | 2-Arylquinazolin-4-one Hydrophobic cavity PARP Tankyrase WNT |
Issue Date: | 2016 | Journal: | European Journal of Medicinal Chemistry | Abstract: | Tankyrases (TNKSs), members of the PARP (Poly(ADP-ribose)polymerases) superfamily of enzymes, have gained interest as therapeutic drug targets, especially as they are involved in the regulation of Wnt signalling. A series of 2-arylquinazolin-4-ones with varying substituents at the 8-position was synthesised. An 8-methyl group (compared to 8-H, 8-OMe, 8-OH), together with a 4′-hydrophobic or electron-withdrawing group, provided the most potency and selectivity towards TNKSs. Co-crystal structures of selected compounds with TNKS-2 revealed that the protein around the 8-position is more hydrophobic in TNKS-2 compared to PARP-1/2, rationalising the selectivity. The NAD+-binding site contains a hydrophobic cavity which accommodates the 2-aryl group; in TNKS-2, this has a tunnel to the exterior but the cavity is closed in PARP-1. 8-Methyl-2-(4-trifluoromethylphenyl)quinazolin-4-one was identified as a potent and selective inhibitor of TNKSs and Wnt signalling. This compound and analogues could serve as molecular probes to study proliferative signalling and for development of inhibitors of TNKSs as drugs. | URI: | http://hdl.handle.net/10553/52422 http://hdl.handle.net/10553/121991 |
ISSN: | 0223-5234 | DOI: | 10.1016/j.ejmech.2016.04.041 | Source: | European Journal of Medicinal Chemistry [ISSN 0223-5234], v. 118, p. 316-327, (Agosto 2016) |
Appears in Collections: | Artículos |
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.